Novo Nordisk Receives FDA Warning Letter Over Unreported Side Effects of Ozempic

Novo Nordisk Receives Warning Letter from FDA Over Ozempic Reporting

Company Overview Novo Nordisk, a Danish drugmaker, has received a warning letter from the US Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients using Ozempic. The diabetes drug, now widely used for weight management, has known side effects including nausea, vomiting, diarrhea, abdominal pain, constipation, and fatigue.

Regulatory Issues The FDA's warning letter, dated March 5, noted that the cases involved two deaths and one suicide. However, the agency did not specify whether these deaths or other reported side effects were directly linked to Ozempic. The FDA has flagged several company procedures as noncompliant, including a policy that allowed potential adverse events to be withheld if the reporter believed the issue was unrelated to the drug.

Market Impact Novo Nordisk's shares declined by 3.3% in Copenhagen following the announcement. Since January, the shares have declined by 22%. The FDA said that the company has yet to demonstrate how its planned changes will prevent similar violations in the future.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Competitor Comparison Novo Nordisk is struggling to regain patients in the expanding obesity drug market, where it has fallen behind competitor Eli Lilly & Co. The US remains the largest market for these medications.

Action Plan Novo Nordisk has stated that it will address the FDA's concerns "expeditiously and holistically." The company has been working with the FDA to develop an action plan since an inspection in 2025.

GLP-1 Receptor Agonists Despite the risks associated with GLP-1 receptor agonists, such as Ozempic, these medications continue to be widely used for weight loss. The FDA has instructed companies to remove suicide-related warnings from weight-loss drug labels, citing a recent review that found no evidence that GLP-1 drugs increase the risk of suicidal thoughts or behaviors.